Cargando…

Correction to: Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis

Detalles Bibliográficos
Autores principales:	Honda, Hirokazu, Ono, Kota, Akizawa, Tadao, Nitta, Kosaku, Hishida, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828211/ https://www.ncbi.nlm.nih.gov/pubmed/29404801 http://dx.doi.org/10.1007/s10157-017-1519-1

Ejemplares similares

Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis
por: Honda, Hirokazu, et al.
Publicado: (2017)

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study
por: Hasegawa, Takeshi, et al.
Publicado: (2018)

RETRACTED ARTICLE: Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease
por: Nitta, Kosaku, et al.
Publicado: (2013)

Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study
por: Nitta, Kosaku, et al.
Publicado: (2018)

Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study
por: Iimuro, Satoshi, et al.
Publicado: (2019)

Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study
por: Inaguma, Daijo, et al.
Publicado: (2016)

Hyperbaric area index calculated from ABPM elucidates the condition of CKD patients: the CKD-JAC study
por: Iimuro, Satoshi, et al.
Publicado: (2014)

Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status of Peritoneal Dialysis Patients
por: Eguchi, Aya, et al.
Publicado: (2012)

Correction: The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease
Publicado: (2015)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
por: Akizawa, Tadao, et al.
Publicado: (2019)

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
por: Akizawa, Tadao, et al.
Publicado: (2019)

Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
por: Yamamoto, Hiroyasu, et al.
Publicado: (2019)

Correction: Bed-side measures for diagnosis of low muscle mass, sarcopenia, obesity, and sarcopenic obesity in patients with chronic kidney disease under non-dialysis-dependent, dialysis dependent and kidney transplant therapy
por: Bellafronte, Natália Tomborelli, et al.
Publicado: (2021)

Correction: Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients
por: Motonishi, Shuta, et al.
Publicado: (2018)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events
por: Hara, Takashi, et al.
Publicado: (2020)

Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events
por: Hara, Takashi, et al.
Publicado: (2021)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
por: Tanaka, Tetsuhiro, et al.
Publicado: (2018)

Management of Osteoporosis in Chronic Kidney Disease
por: Nitta, Kosaku, et al.
Publicado: (2017)

Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease
por: Nitta, Kosaku
Publicado: (2010)

Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease
por: Nitta, Kosaku
Publicado: (2010)

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
por: Akizawa, Tadao, et al.
Publicado: (2021)

Correction to: DIALysis or not: Outcomes in older kidney patients with GerIatriC Assessment (DIALOGICA): rationale and design
por: van Oevelen, Mathijs, et al.
Publicado: (2021)

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients
por: Onoda, Noritaka, et al.
Publicado: (2008)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Correction to: White-coat hypertension and incident end‑stage renal disease in patients with non‑dialysis chronic kidney disease: results from the C‑STRIDE Study
por: Wang, Qin, et al.
Publicado: (2020)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Dialysis‐related practice patterns among hemodialysis patients with cancer
por: Nishiwaki, Hiroki, et al.
Publicado: (2018)

Correction: Adipose Tissue-Derived Mesenchymal Stem Cells in Long-Term Dialysis Patients Display Downregulation of PCAF Expression and Poor Angiogenesis Activation
por: Yamanaka, Shuichiro, et al.
Publicado: (2016)

Visceral fat and attribute-based medicine in chronic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2023)

Correction to: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
por: Sinha, Shubhadeep D., et al.
Publicado: (2019)

Correction to: Management of Hypertension in Chronic Kidney Disease
por: Pugh, Dan, et al.
Publicado: (2020)

Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities
por: Fukuhara, Shunichi, et al.
Publicado: (2012)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_546nal8a3mfpi8stsm2nl2jnov